Leerink Swann started coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report published on Monday, The Fly reports. The brokerage issued an outperform rating and a $28.00 price objective on the stock.
Several other equities analysts have also weighed in on the stock. Canaccord Genuity assumed coverage on shares of Castle Biosciences in a research report on Monday. They set a buy rating and a $26.00 price objective on the stock. Robert W. Baird assumed coverage on shares of Castle Biosciences in a research report on Monday. They set an outperform rating and a $27.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus price target of $26.80.
NASDAQ CSTL opened at $22.75 on Monday. Castle Biosciences has a 52-week low of $17.11 and a 52-week high of $24.75.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Recommended Story: Hold Rating
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.